April 24, 2017 4:38 PM ET

Pharmaceuticals

Company Overview of Supernus Pharmaceuticals, Inc.

Company Overview

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. The company’s product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is u...

1550 East Gude Drive

Rockville, MD 20850

United States

Founded in 2005

363 Employees

Phone:

301-838-2500

Key Executives for Supernus Pharmaceuticals, Inc.

Founder, Chief Executive Officer, President, Secretary and Director
Age: 55
Total Annual Compensation: $523.4K
Chief Financial Officer and Vice President
Age: 65
Total Annual Compensation: $330.5K
Chief Medical Officer and Executive Vice President of Research & Development
Age: 64
Total Annual Compensation: $356.4K
Chief Scientific Officer and Senior Vice President of Intellectual Property
Age: 59
Total Annual Compensation: $337.4K
Senior Vice President of Sales and Marketing
Age: 58
Total Annual Compensation: $291.6K
Compensation as of Fiscal Year 2015.

Supernus Pharmaceuticals, Inc. Key Developments

Supernus Pharmaceuticals, Inc. Receives Final FDA Approval for Trokendi XR® for Migraine Prophylaxis in Adults and Adolescents

Supernus Pharmaceuticals, Inc. announced that the Food and Drug Administration (FDA) has granted final approval to the company’s Supplemental New Drug Applications (sNDAs) requesting a label expansion for Trokendi XR to include prophylaxis of migraine headache in adults and adolescents 12 years and older. Supernus was granted tentative approval of one of the two sNDAs in August 2016, with final approval subject to the pediatric exclusivity of the innovator’s drug in the adolescent population, which expired March 28, 2017. Based on IMS prescription data, Topiramate is the most prescribed drug for the treatment of migraine prophylaxis with more than 9 million prescriptions annually. This represents approximately 50% of all IMS prescriptions written for migraine prophylaxis.

Supernus Pharmaceuticals, Inc. Announces Settlement with Actavis on Trokendi XR Patent Litigation

Supernus Pharmaceuticals, Inc. announced that it has entered into a binding term sheet with Actavis Laboratories, FL, Inc. involving the ongoing patent litigation regarding Actavis’ Abbreviated New Drug Application (ANDA) seeking approval to market generic versions of Supernus’ Trokendi XR (extended-release topiramate) capsules. The binding term sheet permits Actavis to begin selling a generic version of Trokendi XR® on January 1, 2023, or earlier under certain circumstances. The binding term sheet will be submitted to the applicable governmental agencies. Supernus intends to continue its vigorous enforcement of its patent rights for Trokendi XR. Patent protection for Trokendi XR® expires no earlier than 2027.

Supernus Pharmaceuticals Settles with Zydus Pharmaceutical & Cadila Healthcare over Litigation Relating to Trokendi Capsules

Supernus Pharmaceuticals announced that it entered into a settlement agreement with Zydus Pharmaceutical (USA) and Cadila Healthcare. The deal involves an ongoing patent litigation regarding Zydus' abbreviated new drug application (ANDA) seeking approval to market generic versions of Supernus' Trokendi XR capsules. The settlement permits Zydus to begin selling a generic version on Jan. 1, 2023, or earlier under certain circumstances.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Supernus Pharmaceuticals, Inc., please visit www.supernus.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.